Company registration number 13510285 (England and Wales)
BIXBIO LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023
PAGES FOR FILING WITH REGISTRAR
BIXBIO LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
BIXBIO LIMITED
BALANCE SHEET
AS AT 31 JULY 2023
31 July 2023
- 1 -
2023
2022
Notes
£
£
£
£
Fixed assets
Tangible assets
3
949
1,424
Investments
4
6
6
955
1,430
Current assets
Debtors
5
78
78
Cash at bank and in hand
47,941
160,428
48,019
160,506
Creditors: amounts falling due within one year
6
(3,663)
(2,609)
Net current assets
44,356
157,897
Total assets less current liabilities
45,311
159,327
Creditors: amounts falling due after more than one year
7
(100,000)
(100,000)
Net (liabilities)/assets
(54,689)
59,327
Capital and reserves
Called up share capital
8
109
109
Share premium account
65,881
65,881
Equity reserve
71,923
71,923
Profit and loss reserves
(192,602)
(78,586)
Total equity
(54,689)
59,327

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 July 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

BIXBIO LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 JULY 2023
31 July 2023
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 20 February 2024 and are signed on its behalf by:
Tyronne McCrindle
James Ross
Director
Director
Company registration number 13510285 (England and Wales)
BIXBIO LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2023
- 3 -
1
Accounting policies
Company information

BixBio Limited is a private company limited by shares incorporated in England and Wales. The registered office is 5th Floor, 111 Charterhouse Street, London, EC1M 6AW.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised when the goods and services have been provided and the right to receive payment is established. Turnover is shown net of VAT and other sales related taxes.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

BIXBIO LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2023
1
Accounting policies
(Continued)
- 4 -

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

BIXBIO LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2023
1
Accounting policies
(Continued)
- 5 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2023
2022
Number
Number
Total
3
3
BIXBIO LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2023
- 6 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 August 2022 and 31 July 2023
1,899
Depreciation and impairment
At 1 August 2022
475
Depreciation charged in the year
475
At 31 July 2023
950
Carrying amount
At 31 July 2023
949
At 31 July 2022
1,424
4
Fixed asset investments
2023
2022
£
£
Shares in group undertakings and participating interests
6
6
5
Debtors
2023
2022
Amounts falling due within one year:
£
£
Other debtors
78
78
6
Creditors: amounts falling due within one year
2023
2022
£
£
Taxation and social security
1,054
-
0
Other creditors
2,609
2,609
3,663
2,609
7
Creditors: amounts falling due after more than one year
2023
2022
£
£
Other creditors
100,000
100,000
BIXBIO LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2023
- 7 -
8
Called up share capital
2023
2022
2023
2022
Ordinary share capital
Number
Number
£
£
Issued and not fully paid
Ordinary shares of 1p each
8,620
8,620
86
86
2023
2022
2023
2022
Preference share capital
Number
Number
£
£
Issued and fully paid
Preference shares of 1p each
2,250
2,250
23
23
Preference shares classified as equity
23
23
Total equity share capital
109
109
2023-07-312022-08-01false20 February 2024CCH SoftwareCCH Accounts Production 2023.300No description of principal activityTyronne McCrindleJames RossDr Nicholas Walkerfalse135102852022-08-012023-07-31135102852023-07-31135102852022-07-3113510285core:OtherPropertyPlantEquipment2023-07-3113510285core:OtherPropertyPlantEquipment2022-07-3113510285core:CurrentFinancialInstrumentscore:WithinOneYear2023-07-3113510285core:CurrentFinancialInstrumentscore:WithinOneYear2022-07-3113510285core:Non-currentFinancialInstrumentscore:AfterOneYear2023-07-3113510285core:Non-currentFinancialInstrumentscore:AfterOneYear2022-07-3113510285core:CurrentFinancialInstruments2023-07-3113510285core:CurrentFinancialInstruments2022-07-3113510285core:ShareCapital2023-07-3113510285core:ShareCapital2022-07-3113510285core:SharePremium2023-07-3113510285core:SharePremium2022-07-3113510285core:OtherReservesSubtotal2023-07-3113510285core:OtherReservesSubtotal2022-07-3113510285core:RetainedEarningsAccumulatedLosses2023-07-3113510285core:RetainedEarningsAccumulatedLosses2022-07-3113510285bus:Director12022-08-012023-07-3113510285bus:Director22022-08-012023-07-3113510285core:FurnitureFittings2022-08-012023-07-31135102852021-07-142022-07-3113510285core:OtherPropertyPlantEquipment2022-07-3113510285core:OtherPropertyPlantEquipment2022-08-012023-07-3113510285core:WithinOneYear2023-07-3113510285core:WithinOneYear2022-07-3113510285core:Non-currentFinancialInstruments2023-07-3113510285core:Non-currentFinancialInstruments2022-07-3113510285bus:PrivateLimitedCompanyLtd2022-08-012023-07-3113510285bus:SmallCompaniesRegimeForAccounts2022-08-012023-07-3113510285bus:FRS1022022-08-012023-07-3113510285bus:AuditExemptWithAccountantsReport2022-08-012023-07-3113510285bus:Director32022-08-012023-07-3113510285bus:FullAccounts2022-08-012023-07-31xbrli:purexbrli:sharesiso4217:GBP